Noah Rosenberg
About Noah Rosenberg
Noah Rosenberg serves as the Chief Medical Officer at Travere Therapeutics, where he has worked since 2018. He has held various leadership roles in medical affairs and clinical development across multiple pharmaceutical companies, including Esperion Therapeutics, Sanofi, and Pfizer.
Current Position at Travere Therapeutics
Noah Rosenberg serves as the Chief Medical Officer at Travere Therapeutics, a role he has held since 2018. Based in San Diego, California, he is responsible for overseeing the company's medical strategy and operations. His leadership contributes to the development and implementation of innovative therapies aimed at addressing unmet medical needs.
Previous Experience in the Pharmaceutical Industry
Rosenberg has extensive experience in the pharmaceutical industry, having held several senior positions. He was the Chief Medical Officer at Esperion Therapeutics from 2012 to 2014. Prior to that, he worked at Forest Laboratories (now Allergan) as Senior Medical Director for Clinical Development in Metabolism from 2009 to 2011 and as Executive Medical Director, Head of CV/Metabolism, Clinical Development from 2011 to 2012. His tenure at Sanofi as Senior Director of Medical Affairs - Metabolism lasted from 2005 to 2009, and he also served as Medical Director for the CV/Metabolic Area at Pfizer from 2001 to 2005.
Medical Training and Education
Noah Rosenberg completed his medical education at Drexel University College of Medicine, earning his MD from 1989 to 1993. He furthered his training with an internship and residency in Internal Medicine at Mount Sinai School of Medicine of New York University from 1993 to 1996. His undergraduate studies were completed at The Johns Hopkins University, where he achieved a BA in Natural Sciences from 1985 to 1989.
Clinical Experience
Rosenberg has clinical experience as an Attending Physician at The Mount Sinai Hospital from 1996 to 2000, where he practiced for four years. He also served as a Student Health Doctor at The New School for one year from 2000 to 2001. His clinical background supports his roles in medical affairs and development within the pharmaceutical sector.